Genital Warts Treatment Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Genital warts are a common sexually transmitted infection (STI) that is passed on by vaginal and anal intercourse, sharing sex toys, and rarely, by oral sex. There are various treatments that are available for the treatment of genital warts, which include cream or liquid ointments, surgery for removing warts, etc.

Market players are focusing on research activities for the development of treatment for genital warts. This is expected to aid in the growth of the global genital warts treatment market over the forecast period.

For instance, in November 2021, Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced positive results for its Phase II CARE-1 clinical study of VP-102, a novel topical therapy containing a solution of 0.7% (w/v) cantharidin in a proprietary single-use applicator, developed for the treatment of external genital warts (EGW).

VP-102 achieved positive results on both the primary endpoint of complete clearance of all treatable EGW.

Market Dynamics

Market players and research institutes are indulged in conducting research and development, in order to develop treatment for genital warts. This is expected to increase the growth of the global genital warts treatment market over the forecast period.

For instance, in July 2018, Cassiopea SpA, a specialty pharmaceutical company, announced the availability of proof of concept for its Phase II clinical trial of 'CB-06-02', which is a topical 15% immune modulator tellurium-based gel designed for the treatment of genital warts at an extreme level. The proof of concept indicated the complete clearance or statistically significant reduction of genital warts in women. The trial is currently undergoing with various other endpoints.

Key features of the study:

• This report provides in-depth analysis of the global genital warts treatment market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global genital warts treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Sanofi S.A., AbbVie Inc., Perrigo Company PLC, 3M, Lee's Pharmaceutical Holdings Ltd, Cassiopea, Glenmark Pharmaceuticals, Bausch Health, and Novartis International AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global genital warts treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genital warts treatment market

Detailed Segmentation:

• Global Genital Warts Treatment Market, By Drug Type:
  • Imiquimod
  • Podophyllin and Podofilox
  • Trichloroacetic Acid
  • Sinecatechins
  • Others
• Global Genital Warts Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Genital Warts Treatment Market, By Region:
  • North America
    • By Drug Type
    • Imiquimod
    • Podophyllin and Podofilox
    • Trichloroacetic Acid
    • Sinecatechins
    • Others
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • U.S.
    • Canada
  • Latin America
    • By Drug Type
    • Imiquimod
    • Podophyllin and Podofilox
    • Trichloroacetic Acid
    • Sinecatechins
    • Others
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Drug Type
    • Imiquimod
    • Podophyllin and Podofilox
    • Trichloroacetic Acid
    • Sinecatechins
    • Others
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Drug Type
    • Imiquimod
    • Podophyllin and Podofilox
    • Trichloroacetic Acid
    • Sinecatechins
    • Others
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Drug Type
    • Imiquimod
    • Podophyllin and Podofilox
    • Trichloroacetic Acid
    • Sinecatechins
    • Others
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Drug Type
    • Imiquimod
    • Podophyllin and Podofilox
    • Trichloroacetic Acid
    • Sinecatechins
    • Others
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country/Region
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Sanofi S.A.*
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • AbbVie Inc.
  • Perrigo Company PLC
  • 3M
  • Lee's Pharmaceutical Holdings Ltd
  • Cassiopea
  • Glenmark Pharmaceuticals
  • Bausch Health
  • Novartis International AG

"*" marked represents similar segmentation in other categories in the respective section.